"10.1371_journal.pone.0120877","plos one","2015-04-01T00:00:00Z","Mayer N Fishman; Jin Tomshine; William J Fulp; Pamela K Foreman","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America; Blue Ocean Pharma LLC, Annandale, New Jersey, United States of America","Conceived and designed the experiments: MNF JT PKF. Analyzed the data: MNF JT WJF PKF. Contributed reagents/materials/analysis tools: MNF JT WJF PKF. Wrote the paper: MNF JT WJF PKF.","Mayer Fishman declares the following interests: (1) Participation as an investigator in clinical trials using sorafenib in RCC therapy, including payment to employer, Moffitt Cancer Center; (2) Remuneration for participation in advisory boards with Bayer & Onyx regarding sorafenib in RCC therapy; (3) Remuneration for presentations as a speaker regarding on-label use of sorafenib in RCC. Pamela Foreman and Jin Tomshine are employed by Blue Ocean Pharma LLC. Support for this manuscript was provided by Onyx Pharmaceuticals, an Amgen subsidiary. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","04","Mayer N Fishman","MNF",4,TRUE,3,NA,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
